FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912363942> ?p ?o ?g. }

• W2912363942 endingPage "7" @default.
• W2912363942 startingPage "7" @default.
• W2912363942 abstract "7 Background: Esophagectomy (E) is the standard of care for stage I esophageal squamous cell carcinoma (ESCC), while chemoradiotherapy (CRT) is a treatment option. A parallel-group controlled trial including randomized arms to confirm the non-inferiority of CRT to E for stage IA ESCC was conducted. Methods: Patients (pts) with thoracic ESCC, adenosquamous cell, or basaloid cell carcinoma with stage IA (T1bN0M0), age 20 to 75, performance status 0 to 1, and adequate organ function were eligible. If pts accepted randomization, they were randomly allocated to E with 2-3 field lymph node dissection (arm A) or CRT (arm B). However, if pts had a preference and refused randomization, they were allocated to pts preference arm, E (arm C) or CRT (arm D). CRT consisted of cisplatin and 5-FU, with radiation at the dose of 60 Gy concurrently. The primary endpoint was overall survival (OS) of arm A and B, secondary endpoint included OS of arm C and D using inverse probability weighting with propensity score. The planned sample size in arm A and B was 114 pts in total with one-sided alpha of 10%, power of 75% and non-inferiority margin of HR as 1.78. The sample size in arm C and D was at least 156 pts in each arm with one-sided alpha of 2.5%, power of 85% and non-inferiority margin of HR as 1.78. Results: Between December 2006 and February 2013, 379 (Arm A: 4, B: 7, C: 209 C, D: 159) pts were enrolled. Primary endpoint was not calculated due to small number of randomized arms. Patients characteristics of arm C and D were as follows; median age: 62 and 65, male (%): 82.8 and 88.1, PS 0 (%): 99.5 and D 98.1. All histologic type was SCC except one basaloid cell carcinoma in arm C. The 3- and 5-year OS were 94.7% and 86.5% in arm C, and 93.1% and 85.5% in arm D (adjusted HR 1.05; 95% CI 0.67-1.64 [< 1.78]).Treatment related death were observed in two pts in arm C and none in arm D. Conclusions: Though the accrual of randomized arms was shortened, CRT showed trend toward non-inferiority compared to E in pts preference arms. CRT is considered as a treatment option for stage IA ESCC with organ preservation. Clinical trial information: UMIN000000551." @default.
• W2912363942 created "2019-02-21" @default.
• W2912363942 creator A5002558811 @default.
• W2912363942 creator A5003123255 @default.
• W2912363942 creator A5005598571 @default.
• W2912363942 creator A5008895945 @default.
• W2912363942 creator A5009691281 @default.
• W2912363942 creator A5013635419 @default.
• W2912363942 creator A5018112691 @default.
• W2912363942 creator A5018261108 @default.
• W2912363942 creator A5021782707 @default.
• W2912363942 creator A5023875635 @default.
• W2912363942 creator A5024909015 @default.
• W2912363942 creator A5039783762 @default.
• W2912363942 creator A5039941002 @default.
• W2912363942 creator A5058393024 @default.
• W2912363942 creator A5062944002 @default.
• W2912363942 creator A5067160675 @default.
• W2912363942 creator A5082832235 @default.
• W2912363942 creator A5083884798 @default.
• W2912363942 creator A5087755446 @default.
• W2912363942 date "2019-02-01" @default.
• W2912363942 modified "2023-10-16" @default.
• W2912363942 title "Parallel-group controlled trial of esophagectomy versus chemoradiotherapy in patients with clinical stage I esophageal carcinoma (JCOG0502)." @default.
• W2912363942 doi "https://doi.org/10.1200/jco.2019.37.4_suppl.7" @default.
• W2912363942 hasPublicationYear "2019" @default.
• W2912363942 type Work @default.
• W2912363942 sameAs 2912363942 @default.
• W2912363942 citedByCount "18" @default.
• W2912363942 countsByYear W29123639422019 @default.
• W2912363942 countsByYear W29123639422020 @default.
• W2912363942 countsByYear W29123639422021 @default.
• W2912363942 countsByYear W29123639422022 @default.
• W2912363942 countsByYear W29123639422023 @default.
• W2912363942 crossrefType "journal-article" @default.
• W2912363942 hasAuthorship W2912363942A5002558811 @default.
• W2912363942 hasAuthorship W2912363942A5003123255 @default.
• W2912363942 hasAuthorship W2912363942A5005598571 @default.
• W2912363942 hasAuthorship W2912363942A5008895945 @default.
• W2912363942 hasAuthorship W2912363942A5009691281 @default.
• W2912363942 hasAuthorship W2912363942A5013635419 @default.
• W2912363942 hasAuthorship W2912363942A5018112691 @default.
• W2912363942 hasAuthorship W2912363942A5018261108 @default.
• W2912363942 hasAuthorship W2912363942A5021782707 @default.
• W2912363942 hasAuthorship W2912363942A5023875635 @default.
• W2912363942 hasAuthorship W2912363942A5024909015 @default.
• W2912363942 hasAuthorship W2912363942A5039783762 @default.
• W2912363942 hasAuthorship W2912363942A5039941002 @default.
• W2912363942 hasAuthorship W2912363942A5058393024 @default.
• W2912363942 hasAuthorship W2912363942A5062944002 @default.
• W2912363942 hasAuthorship W2912363942A5067160675 @default.
• W2912363942 hasAuthorship W2912363942A5082832235 @default.
• W2912363942 hasAuthorship W2912363942A5083884798 @default.
• W2912363942 hasAuthorship W2912363942A5087755446 @default.
• W2912363942 hasConcept C121608353 @default.
• W2912363942 hasConcept C126322002 @default.
• W2912363942 hasConcept C141071460 @default.
• W2912363942 hasConcept C146357865 @default.
• W2912363942 hasConcept C151730666 @default.
• W2912363942 hasConcept C168563851 @default.
• W2912363942 hasConcept C203092338 @default.
• W2912363942 hasConcept C204243189 @default.
• W2912363942 hasConcept C2777297899 @default.
• W2912363942 hasConcept C2778424827 @default.
• W2912363942 hasConcept C2779742542 @default.
• W2912363942 hasConcept C509974204 @default.
• W2912363942 hasConcept C71924100 @default.
• W2912363942 hasConcept C86803240 @default.
• W2912363942 hasConceptScore W2912363942C121608353 @default.
• W2912363942 hasConceptScore W2912363942C126322002 @default.
• W2912363942 hasConceptScore W2912363942C141071460 @default.
• W2912363942 hasConceptScore W2912363942C146357865 @default.
• W2912363942 hasConceptScore W2912363942C151730666 @default.
• W2912363942 hasConceptScore W2912363942C168563851 @default.
• W2912363942 hasConceptScore W2912363942C203092338 @default.
• W2912363942 hasConceptScore W2912363942C204243189 @default.
• W2912363942 hasConceptScore W2912363942C2777297899 @default.
• W2912363942 hasConceptScore W2912363942C2778424827 @default.
• W2912363942 hasConceptScore W2912363942C2779742542 @default.
• W2912363942 hasConceptScore W2912363942C509974204 @default.
• W2912363942 hasConceptScore W2912363942C71924100 @default.
• W2912363942 hasConceptScore W2912363942C86803240 @default.
• W2912363942 hasIssue "4_suppl" @default.
• W2912363942 hasLocation W29123639421 @default.
• W2912363942 hasOpenAccess W2912363942 @default.
• W2912363942 hasPrimaryLocation W29123639421 @default.
• W2912363942 hasRelatedWork W2078913685 @default.
• W2912363942 hasRelatedWork W2084845148 @default.
• W2912363942 hasRelatedWork W2398853979 @default.
• W2912363942 hasRelatedWork W2415196927 @default.
• W2912363942 hasRelatedWork W2431147081 @default.
• W2912363942 hasRelatedWork W2466280954 @default.
• W2912363942 hasRelatedWork W2897898837 @default.
• W2912363942 hasRelatedWork W2912347445 @default.
• W2912363942 hasRelatedWork W2953828307 @default.
• W2912363942 hasRelatedWork W2967409375 @default.
• W2912363942 hasVolume "37" @default.
• W2912363942 isParatext "false" @default.

• next